News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.
The German company offers rare disease genetic tests and services for clinical applications, as well as to support drug discovery and development programs.
The German company offers rare disease genetic tests and services for clinical applications and to support clients' drug discovery and development programs.
The final guidance seeks to streamline the process, which has typically required separate submission processes for the drug and the device.
According to the DOJ, the company also accepted a 25-year ban on participating in any federal healthcare program.
The two companies will work together to bring the point-of-care pretreatment diagnostic based on the XDX-01 biomarker to market in 2020.
This webinar will discuss the use of next-generation sequencing and an optimized variant interpretation workflow to increase diagnostic yield in complex clinical cases.